Navigation Links
Thermage Reports Third Quarter Financial Results and Provides Information Regarding Reliant's Results

HAYWARD, Calif., Nov. 10 /PRNewswire-FirstCall/ -- Thermage, Inc. (Nasdaq: THRM), a leader in non-invasive tissue tightening in the aesthetic industry, today reported financial results for the third quarter ended September 30, 2008. Reliant Technologies, Inc. also reported its financial results for the third quarter.

Thermage revenue for the third quarter of 2008 was $13.0 million, a decline of 6% from $13.9 million for the third quarter of 2007. Domestic revenue decreased 10% and international revenue fell 1% from the third quarter of 2007. Gross margin for the quarter was 75.4% as compared to 77.6% for the same period last year. Third quarter operating expenses declined from the prior year by $0.4 million, or 3%, to $10.6 million. Net loss for the quarter was $1.1 million, or $0.05 per share, compared to net income of $0.4 million, or $0.02 per diluted share, in the third quarter of 2007. The third quarter of 2008 included a $0.9 million loss, or $0.03 per share, associated with the company's investment in a Lehman Brothers bond. Non-GAAP (1) net income for the third quarter of 2008 was $0.7 million, or $0.03 per diluted share, compared to non-GAAP (1) net income of $1.6 million, or $0.07 per diluted share, for the prior year period.

Third quarter 2008 revenue for Reliant totaled $19.9 million, 22% over the $16.3 million in revenue in the third quarter of the prior year. Reliant's operating loss for the third quarter of 2008 was $1.6 million on a GAAP basis and included approximately $1.6 million in stock based compensation charges and approximately $1.1 million in transaction expenses related to the pending merger with Thermage.

On a combined pro forma basis, revenue for the third quarter of 2008 for both companies would have totaled $32.9 million. This represents a growth rate of approximately 9% from the pro forma combined revenue of the two companies of $30.1 million in the third quarter of 2007.

"This was a challenging quarter for the industry. The poor economic climate and tight credit conditions resulted in physicians delaying purchases and a slowdown in end-user demand," said Stephen J. Fanning, Chairman, President and Chief Executive Officer. "While Thermage revenue declined slightly from the prior year, our gross margin of 75% remains one of the highest in the industry. In addition, we exhibited good control of our operating expenses and generated approximately $1.4 million in cash from operations in the quarter."

"Reliant's growth for the quarter was the highest reported in the aesthetic energy device industry," Mr. Fanning continued. "With growing acceptance of its Fraxel products and procedures for skin resurfacing and rejuvenation earlier, Reliant generated strong growth, despite the difficult environment. We are focused on closing the Reliant transaction and completing the integration as quickly as possible. The Reliant acquisition offers significant opportunities for an expanded market presence and cost synergies."

"We anticipate that the environment will remain challenging. However, we believe that the merger of Thermage and Reliant joins the two leading brands and innovators in aesthetic device technology. Both companies have business models focused on generating substantial recurring revenue that should serve to help us weather current economic conditions and ultimately result in strengthening our leadership position in the industry," concluded Mr. Fanning.

Due to the pending completion of the Reliant acquisition and the uncertain economic environment, Thermage is withdrawing previous guidance for full year 2008.

Non-GAAP Presentation

(1) To supplement the condensed financial information presented on a GAAP basis, management has provided non-GAAP net income, and non-GAAP earnings per share measures that exclude the impact of all stock-based compensation expenses, loss on investments, and merger related costs, all net of income taxes. The Company believes that these non-GAAP financial measures provide investors with insight into what is used by management to conduct a more meaningful and consistent comparison of the Company's ongoing operating results and trends, compared with historical results. This presentation is also consistent with management's internal use of the measure, which it uses to measure the performance of ongoing operating results, against prior periods and against our internally developed targets. A table reconciling the GAAP financial measures to the non-GAAP measures is included in the condensed financial information attached to this release.

Conference Call

The conference call is scheduled to begin at 1:30 p.m. PT (4:30 p.m. ET) on November 10, 2008. The call will be broadcast live over the Internet hosted at the Investor Relations section of the Company's website at In addition, you may call to listen to the live broadcast: 800-218-0530 for domestic participants and 303-262-2190 for international participants.

A taped replay of the conference call will also be available beginning approximately one hour after the call's conclusion and will remain accessible for seven days. This replay can be accessed by dialing 800-405-2236 for domestic callers and 303-590-3000 for international callers. Both callers will need to use the Passcode 11120695#. An archived webcast will also be available at

About Thermage, Inc.

Thermage's innovative technology provides a unique non-invasive procedure designed to tighten and contour skin, significantly expanding the non-invasive aesthetic applications physicians can offer to the rapidly growing "anti-aging" market. For more information, call 1-510-259-7117 or visit

This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Specifically, statements concerning the pending merger with Reliant and related integration as well as the uncertain economic environments are forward-looking statements within the meaning of the Safe Harbor. Forward-looking statements are based on management's current, preliminary expectations and are subject to risks and uncertainties, which may cause Thermage's actual results to differ materially from the statements contained herein including but not limited to market acceptance and demand of current and future products among physicians and patients, our ability to successfully integrate the operations of Reliant and realize synergies, the potential impact of general economic conditions on the demand for our products, risks inherent with third-party supply and distribution networks, risks inherent to future sales growth, and the ability to execute proposed initiatives. Further information on potential risk factors that could affect Thermage's business and its financial results are detailed in its Form 10-K for the year ended December 31, 2007, its Form 10-Q for the quarter ended June 30, 2008 and other reports as filed from time to time with the Securities and Exchange Commission. Undue reliance should not be placed on forward-looking statements, especially guidance on future financial performance, which speaks only as of the date they are made. Thermage undertakes no obligation to update publicly any forward-looking statements to reflect new information, events or circumstances after the date they were made, or to reflect the occurrence of unanticipated events.

Additional Information and Where You Can Find It

This communication may be deemed to be solicitation material in respect of the proposed transaction between Thermage and Reliant. In connection with the transaction, Thermage has filed a registration statement on Form S-4 with the SEC containing a proxy statement/prospectus/ information statement. The proxy statement/prospectus/information statement will be mailed to the stockholders of Thermage and Reliant. Investors and security holders of Thermage and Reliant are urged to read the proxy statement/prospectus/information statement when it becomes available because it will contain important information about Thermage, Reliant and the proposed transaction. The proxy statement/prospectus/information statement (when it becomes available), and any other documents filed by Thermage with the SEC, may be obtained free of charge at the SEC's web site at In addition, investors and security holders may obtain free copies of the documents filed with the SEC by Thermage by contacting Thermage Investor Relations by e-mail at or by telephone at (510) 259-7117. Investors and security holders are urged to read the proxy statement/prospectus/information statement and the other relevant materials when they become available before making any voting or investment decision with respect to the proposed transaction.

Thermage, Inc.


(in thousands of dollars, except share and per share data)


Three Months Ended Nine Months Ended

September 30, September 30,

2008 2007 2008 2007

Net revenue $13,020 $13,865 $47,132 $46,519

Cost of revenue 3,209 3,111 11,662 12,081

Gross margin 9,811 10,754 35,470 34,438

Operating expenses:

Sales and marketing 5,915 6,016 20,330 19,205

Research and development 2,150 2,282 7,054 6,980

General and administrative 2,575 2,695 10,173 8,162

Total operating expenses 10,640 10,993 37,557 34,347

Income (loss) from

operations (829) (239) (2,087) 91

Interest and other income 635 662 1,781 1,846

Loss on investments (863) - (863) -

Income (loss) before

income taxes (1,057) 423 (1,169) 1,937

Provision for income taxes (89) - (175) (147)

Net income (loss) $(1,146) $423 $(1,344) $1,790

Net income (loss) per

share - basic $(0.05) $0.02 $(0.06) $0.08

Net income (loss) per

share - diluted $(0.05) $0.02 $(0.06) $0.07

Weighted average shares

outstanding used in

calculating net income

(loss) per share:

Basic 24,067,548 23,364,409 23,861,079 23,151,949

Diluted 24,067,548 24,882,614 23,861,079 24,825,621



(in thousands, except share and per share data)


Three Months Ended Nine Months Ended

September 30, September 30,

2008 2007 2008 2007

Income (loss) from

operations $(829) $(239) $(2,087) $91

Non-GAAP adjustments to

income (loss) from


Merger related costs 165 - 1,134 -

Stock-based compensation 887 1,222 2,789 3,705

Non-GAAP income from

operations $223 $983 $1,836 $3,796

GAAP net income (loss) $(1,146) $423 $(1,344) $1,790

Non-GAAP adjustments to

net income (loss):

Merger related costs, net

of taxes 131 - 1,075 -

Loss on investments, net

of taxes 863 - 863 -

Stock-based compensation,

net of taxes 887 1,222 2,789 3,705

Non-GAAP net income $735 $1,645 $3,383 $5,495

GAAP basic net income

(loss) per share $(0.05) $0.02 $(0.06) $0.08

Non-GAAP adjustments to

basic income (loss) per


Merger related costs 0.01 - 0.05 -

Loss on investments 0.03 - 0.03 -

Stock-based compensation 0.04 0.05 0.12 0.16

Non-GAAP basic net income

per share $0.03 $0.07 $0.14 $0.24

Non-GAAP diluted net

income per share $0.03 $0.07 $0.14 $0.23

GAAP weighted average

shares outstanding used

in calculating basic net

income (loss) per share 24,067,548 23,364,409 23,861,079 23,151,949

Adjustments for dilutive

potential common stock 838,410 549,052 1,057,632 585,145

Weighted average shares

outstanding used in

calculating non-GAAP

diluted net income (loss)

per share 24,905,958 23,913,461 24,918,711 23,737,094

Thermage, Inc.


(in thousands of dollars, except share and per share data)


September 30, December 31,

2008 2007


Current assets:

Cash and cash equivalents $21,236 $13,650

Marketable investments 24,684 38,707

Accounts receivable, net 5,928 4,809

Inventories, net 6,823 6,639

Prepaid expenses and other current

assets 1,401 1,782

Total current assets 60,072 65,587

Property and equipment, net 3,132 3,000

Notes and interest receivable 5,164 -

Other assets 1,784 140

Total assets $70,152 $68,727



Accounts payable $2,517 $1,341

Accrued liabilities 6,359 6,850

Current portion of deferred revenue 1,472 1,544

Customer deposits 57 18

Total current liabilities 10,405 9,753

Deferred revenue, net of current

portion 529 601

Other liabilities 322 255

Total liabilities 11,256 10,609

Stockholders' equity:

Common stock, $0.001 par value:

100,000,000 shares authorized

24,082,735 and 23,605,415 shares

issued and outstanding at September

30, 2008 and December 31, 2007,

respectively 24 24

Additional paid-in capital 103,127 99,588

Deferred stock-based compensation (2) (4)

Accumulated other comprehensive

income (loss) (1,400) 19

Accumulated deficit (42,853) (41,509)

Total stockholders' equity 58,896 58,118

Total liabilities and stockholders'

equity $70,152 $68,727

SOURCE Thermage, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Thermage Discloses Preliminary 3Q 2008 Results for Thermage and Reliant
2. Thermage, Inc. to Present at the Maxim Group Growth Conference
3. Thermage Announces Second Quarter 2008 Financial Results
4. Thermage, Inc. to Present at the Fourth Annual Collins Stewart Growth Conference
5. Thermage and Reliant Technologies to Join Forces
6. Thermage, Inc. to Present at the Bank of America 2008 Healthcare Conference
7. Thermage, a Leading Aesthetic Medical Device Company, Announces First Time Exhibitor Status at ACOG Meeting
8. Thermage, Inc. Announces First Quarter 2008 Results Release Date and Conference Call
9. Thermage, Inc. Announces Initial Shipments of Cellulite Product
10. Thermage Announces Fourth Quarter and Full Year 2007 Financial Results
11. Thermage, Inc. Announces Fourth Quarter 2007 Results Release Date and Conference Call
Post Your Comments:
(Date:10/13/2017)... ... October 13, 2017 , ... “The Journey: From the Mountains to ... to save lost souls in the Philippines. “The Journey: From the Mountains to the ... teacher of the Bible. She has taught all ages and currently teaches a class ...
(Date:10/12/2017)... ... October 12, 2017 , ... CitiDent ... sleep apnea using cutting-edge Oventus O2Vent technology. As many as 18 million ... by frequent cessation in breathing. Oral appliances can offer significant relief to about ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... IsoComforter, Inc. ... products, announced today the introduction of an innovative new design of the shoulder pad. ... so you get maximum comfort while controlling your pain while using cold therapy. By ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... ... drug delivery system that we intend to develop to enable prevention of a ... lead to severe hearing loss, especially in pediatric patients. For cisplatin, hearing loss ...
(Date:10/12/2017)... ... October 12, 2017 , ... Leading pediatric oncology experts at ... D.C., for the 49th Congress of the International Society of Paediatric Oncology ... the Center for Cancer and Blood Disorders at Children’s National, and Stephen ...
Breaking Medicine News(10 mins):
(Date:10/10/2017)...   West Pharmaceutical Services, Inc. (NYSE: WST), ... administration, today shared the results of a study highlighting ... intradermal administration of polio vaccines. The study results were ... 2017 by Dr. Ondrej Mach , Clinical Trials ... (WHO), and recently published in the journal Vaccine. ...
(Date:10/4/2017)... 2017  South Korean-based healthcare product Development Company I.M. ... on Kickstarter. The device will educate the user about ... better efficiency compared to the dated and pricey CPR ... efficacy of the compression for a more informed CPR ... to raise $5,000. ...
(Date:10/2/2017)... Mich. , Oct. 2, 2017 Diplomat ... 8th Day Software and Consulting, LLC , and ... 8th Day Software, based in Tennessee ... LLC. 8th Day expands EnvoyHealth,s service offerings for health ... development. "In an ...
Breaking Medicine Technology: